ARTICLE | Company News
Array BioPharma, Aslan deal
July 18, 2011 7:00 AM UTC
Array granted Aslan exclusive, worldwide rights to develop cancer candidate ARRY-543. Aslan will develop the inhibitor of EGFR and HER2 through Phase II testing in gastric cancer and other tumor ty...